|
|
Volumn 51, Issue 4, 2011, Pages 438-440
|
|
Novel targets for the treatment of heart failure: Perspectives from a heart failure clinician and trialist
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BIOLOGICAL MARKER;
CAPTOPRIL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ENDOTHELIN RECEPTOR ANTAGONIST;
FLOSEQUINAN;
CARDIAC RESYNCHRONIZATION THERAPY;
CARDIOMYOPATHY;
CLINICAL TRIAL (TOPIC);
DEFIBRILLATION;
DRUG APPROVAL;
EDITORIAL;
HEART ARRHYTHMIA;
HEART EJECTION FRACTION;
HEART FAILURE;
HOSPITAL ADMISSION;
HUMAN;
INCIDENCE;
LEFT VENTRICULAR ASSIST DEVICE;
MEDICAL RESEARCH;
MORTALITY;
MYOCARDIAL DISEASE;
OUTCOME ASSESSMENT;
OUTPATIENT;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
SUDDEN DEATH;
SURVIVAL RATE;
TREATMENT OUTCOME;
UNITED STATES;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
CLINICAL TRIALS AS TOPIC;
DRUG DISCOVERY;
FEMALE;
HEART FAILURE;
HUMANS;
MALE;
RENIN-ANGIOTENSIN SYSTEM;
TRANSLATIONAL MEDICAL RESEARCH;
UNITED STATES;
|
|
EID: 80052805670
PISSN: 00222828
EISSN: 10958584
Source Type: Journal
DOI: 10.1016/j.yjmcc.2011.03.016 Document Type: Editorial |
|
Times cited : (8)
|
|
References (8)
|
